Toggle light / dark theme

Facilitating Novel Health-Tech and Bio-Medical Innovations For Over 9 Million Veterans — Dr. Rachel Ramoni, Chief of R&D, U.S. Department of Veterans Affairs.


Dr. Rachel Ramoni, is the Chief Research and Development Officer of the United States Department of Veterans Affairs (VA), where she oversees their nationwide research enterprise, encompassing some 2000 active projects, at more than 100 sites, with a total budget of $2 billion in both direct VA support, and research funding from outside entities such as the National Institutes of Health, other federal agencies, and nonprofit and private organizations.

The United States Department of Veterans Affairs (VA) is a federal Cabinet-level agency that provides comprehensive healthcare services to military veterans at over 1000 VA medical centers and outpatient clinics located throughout the US – It also provides several non-healthcare benefits including disability compensation, vocational rehabilitation, education assistance, home loans, and life insurance; and provides burial and memorial benefits to eligible veterans and family members.

Ditto for Canada…


As US President Biden signs a national mask mandate into law, measures being imposed in the name of protecting public health could create a humanitarian crisis that sees Americans sued by the state and forced into detention camps for breaking pandemic protocols.

The very first executive order Joe Biden signed upon becoming the forty-sixth President of the United States was the national mask mandate he promised at the Democratic National Convention back in August. The order makes face coverings and social distancing mandatory on all federal property and a legal requisite for interstate commerce.

We are creating compelling homegrown solutions in education, health care, agriculture, infrastructure, financial services and new commerce,” Ambani said in his speech. “Each of these solutions, once proven in India, will be offered to the rest of the world to address global challenges.


Mukesh Ambani has spent years trying to turn his inherited oil business into a tech empire. In 2020, that pivot really kicked into overdrive.

Wistar Institute scientists have designed a new class of antimicrobial compound, which, they claim, uniquely combines direct antibiotic killing of pan drug-resistant pathogenic bacteria, with a simultaneous rapid immune response for combating antimicrobial resistance (AMR). The team claims the dual-acting immuno-antibiotics (DAIA) strategy could represent a “landmark” in the fight against AMR.

“We took a creative, double-pronged strategy to develop new molecules that can kill difficult-to-treat infections while enhancing the natural host immune response,” said Farokh Dotiwala, MBBS, PhD, assistant professor in the Vaccine & Immunotherapy Center and lead author of the team’s work, which is reported in Nature, in a paper titled, “IspH inhibitors kill Gram-negative bacteria and mobilize immune clearance.”

The World Health Organization (WHO) has declared AMR to be one of the top 10 global public health threats against humanity, and it is estimated that by 2050, antibiotic-resistant infections could claim 10 million lives each year and impose a cumulative $100 trillion burden on the global economy. The list of bacteria that are becoming resistant to treatment with all available antibiotic options is growing and few new drugs are in the pipeline, creating a pressing need for new classes of antibiotics to prevent public health crises.

Summary: Close adherence to the MIND and Mediterranean diets delayed the onset of Parkinson’s disease by up to 17.4 years in women, and 8.4 years in men.

Source: University of British Columbia.

A new study from UBC researchers suggests a strong correlation between following the MIND and Mediterranean diets and later onset of Parkinson’s disease (PD). While researchers have long known of neuroprotective effects of the MIND diet for diseases like Alzheimer’s and dementia, this study is the first to suggest a link between this diet and brain health for Parkinson’s disease (PD).